SCHEMBL30965463

SCHEMBL30965463

Nc1ccc(-c2ccc(-c3nc4ccc(Cl)cc4o3)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.73
RAB9A P51151 12/20 0.73
KDM4E B2RXH2 8/20 0.73
ALDH1A1 P00352 8/20 0.73
MAPT P10636 8/20 0.73
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
SMN1; SMN2 Q16637 7/20 0.73
HPGD P15428 6/20 0.73
GLA P06280 2/20 0.73
GAA P10253 2/20 0.73
ATM Q13315 2/20 0.59
GFER P55789 2/20 0.59
RXFP1 Q9HBX9 2/20 0.59
PIK3CG P48736 1/20 0.58
NFKB1 P19838 3/20 0.54
NFKB2 Q00653 3/20 0.54
RELA Q04206 3/20 0.54
LMNA P02545 1/20 0.54
CASP3 P42574 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24106599 1.00 NPC1 (0.73) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL2244352 0.98 NPC1 (0.76) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL17199120 0.89 NPC1 (0.81) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL10590678 0.89 SMN1; SMN2 (0.61) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL23748392 0.88 NPC1 (0.73) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL28292707 0.87 RAB9A (0.96) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1734841 0.86 NPC1 (0.76) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL23748387 0.86 SMN1; SMN2 (0.71) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL29622897 0.86 NPC1 (0.76) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL5655662 0.85 NPC1 (0.86) NPC1RAB9AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 NPC1 1454/4885RAB9A 701/4885KDM4E 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.